Zobrazeno 1 - 10
of 81
pro vyhledávání: '"35"'
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Atsushi Sato, Yasushi Tsuji, Takahide Sasaki, Shintaro Nakano, Susumu Sogabe, Atsushi Ishiguro, Hiroshi Nakatsumi, Satoshi Yuki, Yoshito Komatsu, Masayoshi Dazai, Osamu Muto, Yuh Sakata, Hiroyuki Okuda, Kentaro Sawada, Kazuaki Harada, Naoya Sakamoto, Mari Sekiguchi, Yasuyuki Kawamoto, Michio Nakamura, Yoshiaki Shindo
Publikováno v:
Journal of Clinical Oncology. 39:217-217
217 Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased overall survival (OS) compared with PTX alone for advanc
Publikováno v:
Journal of Clinical Oncology. 24:1454-1458
Purpose A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if t
Autor:
Sylke Nagel, Aruna Raghavachar, Ludwig Fischer von Weikersthal, Monika Serke, Ernst-Wilhelm Schmidt, Christine Lautenschlaeger, Hans Schweisfurth, Wolfgang Schuette, Ina Dittrich, Klaus Hans, Thomas Blankenburg, Angelika Reißig
Publikováno v:
Journal of Clinical Oncology. 23:8389-8395
Purpose A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule. Patients and Methods Patients with stage IIIB-IV non–small-cell lung cancer (NSCLC) were randomly
Autor:
Joop De langen, Egbert F. Smit, Sayed M.S. Hashemi, Erik Thunnissen, Kim Monkhorst, Justine L. Kuiper
Publikováno v:
De Langen, J, Kuiper, J L, Thunnissen, E, Hashemi, S M S, Monkhorst, K & Smit, E F 2017, ' Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment. ', Journal of Clinical Oncology, vol. 35 . https://doi.org/10.1200/JCO.2017.35.15_suppl.9042
Journal of Clinical Oncology, 35. American Society of Clinical Oncology
Journal of Clinical Oncology, 35. American Society of Clinical Oncology
9042 Background: HER2 expression as well as amplification has been well recognized in tumor biopsies of pts with an EGFR mutation who developed EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumor responses. M
Publikováno v:
Journal of Clinical Oncology. 16:1844-1848
PURPOSE Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium. We evaluated the combination of paclitaxel and carboplatin in the treatment of advanced cancers of the urothelium. PATIENTS AND METHODS Patients w
Autor:
Matthew A. Williams, Robert B. Livingston, G. K. Ellis, C A Long, R White, C McGuirt, Julie R. Gralow, B B Adamkiewicz
Publikováno v:
Journal of Clinical Oncology. 15:1395-1400
PURPOSE We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgr
Autor:
Al B. Benson, Steven M. Keller, Mark Powell, Lawrence Kleinberg, Arlene A. Forastiere, Pramila R. Anne
Publikováno v:
Journal of Clinical Oncology. 30:69-69
69 Background: E1201 included operable esophageal adenocarcinoma, staged II-IVa by EUS and accrual ended Oct 2004. The primary endpoint was pathologic complete response (pCR), a surrogate endpoint generally associated with survival which did not meet
Autor:
J. Luo, Fei-Man Hsu, Chun-Nan Lin, Hsei-Wei Wang, Jen-Kuang Lee, Jason Chia-Hsien Cheng, C.-H. Hsu, Yu-Ping Lee, A-L Cheng, Yun-Fang Tsai
Publikováno v:
Journal of Clinical Oncology. 27:e15526-e15526
e15526 Background: To assess the feasibility of preoperative induction chemotherapy in addition to concurrent chemoradiotherapy (CCRT) followed by esophagectomy if possible for locally advanced esophageal squamous cell carcinoma (ESCC) with a special
Autor:
Sandra M. Swain, R. P. Shannon, Edward H. Romond, John Bryant, Michael S. Ewer, T. B. Levine, D. L. Keefe, Norman Wolmark, Priya Rastogi, Charles E. Geyer
Publikováno v:
Journal of Clinical Oncology. 25:LBA513-LBA513
LBA513 Background: Trastuzumab (H) has been shown to improve survival in HER2 positive, node-positive breast cancer patients when combined with paclitaxel following AC (Romond NEJM 2005:353;1673–1684). Cardiac dysfunction is the major toxicity asso